MwanzoTRVN • NASDAQ
add
Trevena Inc
Bei iliyotangulia
$ 0.21
Bei za siku
$ 0.20 - $ 0.22
Bei za mwaka
$ 0.19 - $ 1.12
Thamani ya kampuni katika soko
4.03M USD
Wastani wa hisa zilizouzwa
1.81M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | elfu 20.00 | 233.33% |
Matumizi ya uendeshaji wa biashara | 9.81M | -1.88% |
Mapato halisi | -7.68M | 1.80% |
Kiwango cha faida halisi | elfu -38.39 | 70.54% |
Mapato kwa kila hisa | — | — |
EBITDA | -9.79M | 2.46% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 23.55M | -14.16% |
Jumla ya mali | 31.14M | -18.69% |
Jumla ya dhima | 45.79M | 62.74% |
Jumla ya hisa | -14.65M | — |
hisa zilizosalia | 18.34M | — |
Uwiano wa bei na thamani | -0.27 | — |
Faida inayotokana na mali | -68.84% | — |
Faida inayotokana mtaji | -97.91% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -7.68M | 1.80% |
Pesa kutokana na shughuli | -9.42M | 13.37% |
Pesa kutokana na uwekezaji | — | — |
Pesa kutokana na ufadhili | elfu -3.00 | -50.00% |
Mabadiliko halisi ya pesa taslimu | -9.42M | 13.36% |
Mtiririko huru wa pesa | -6.30M | 11.28% |
Kuhusu
Trevena Inc is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
Ilianzishwa
2007
Tovuti
Wafanyakazi
23
